Thymidine Phosphorylase Monoclonal Antibody (P-GF.44C) | Invitrogen MA1-46059 product information

product summary

company name :

Invitrogen

other brands :

NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience

product type :

antibody

product name :

Thymidine Phosphorylase Monoclonal Antibody (P-GF.44C)

catalog :

MA1-46059

quantity :

100 µg

price :

US 470

clonality :

monoclonal

host :

mouse

conjugate :

nonconjugated

clone name :

P-GF.44C

reactivity :

human, mouse, rat

application :

western blot, ELISA, immunohistochemistry, immunocytochemistry, immunoprecipitation, immunohistochemistry - paraffin section

more info or order :

Invitrogen product webpage

citations: 25

Published Application/Species/Sample/Dilution	Reference
immunohistochemistry - paraffin section; human; 1:500	Kim J, Shin E, Kim J, Lee H, Lee D, Kim S, et al. Impact of intratumoral expression levels of fluoropyrimidine-metabolizing enzymes on treatment outcomes of adjuvant S-1 therapy in gastric cancer. PLoS ONE. 2015;10:e0120324 pubmed publisher
immunohistochemistry - paraffin section; human; 1:100	Koumarianou A, Tzeveleki I, Mekras D, Eleftheraki A, Bobos M, Wirtz R, et al. Prognostic markers in early-stage colorectal cancer: significance of TYMS mRNA expression. Anticancer Res. 2014;34:4949-62 pubmed
immunohistochemistry; human; 1:60	Cha Y, Han S, Seol H, Oh D, Im S, Bang Y, et al. Immunohistochemical features associated with sensitivity to lapatinib-plus-capecitabine and resistance to trastuzumab in HER2-positive breast cancer. Anticancer Res. 2014;34:4275-80 pubmed
immunohistochemistry; human; 1:50	Cubillo A, Rodriguez Pascual J, Lopez Rios F, Plaza C, Garcia E, Alvarez R, et al. Phase II Trial of Target-guided Personalized Chemotherapy in First-line Metastatic Colorectal Cancer. Am J Clin Oncol. 2016;39:236-42 pubmed publisher
immunohistochemistry; human; 1:50	Cubillo A, Hernando Requejo O, Garcia Garcia E, Rodriguez Pascual J, de Vicente E, Morelli P, et al. A prospective pilot study of target-guided personalized chemotherapy with intensity-modulated radiotherapy in patients with early rectal cancer. Am J Clin Oncol. 2014;37:117-21 pubmed publisher
ELISA; human; 0.5 ug/ml; loading ...; fig 1d	Starlinger P, Alidzanovic L, Schauer D, Brugger P, Sommerfeldt S, Kuehrer I, et al. Platelet-stored angiogenesis factors: clinical monitoring is prone to artifacts. Dis Markers. 2011;31:55-65 pubmed publisher
immunohistochemistry; human; 1:500	Kim S, Han S, Oh D, Yi N, Kim Y, Im S, et al. Combination chemotherapy with S-1 and platinum in advanced hepatocellular carcinoma. Anticancer Res. 2010;30:5245-50 pubmed
immunohistochemistry - paraffin section; human; 1:100; loading ...; fig 2d	Lee S, Choi Y, Park Y, Kim S, Cho E, Ahn J, et al. Thymidylate synthase and thymidine phosphorylase as predictive markers of capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Cancer Chemother Pharmacol. 2011;68:743-51 pubmed publisher
immunohistochemistry; human; 1:100	Lee S, Park Y, Kim K, Cho E, Ahn Y, Kim K, et al. Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell c. Br J Cancer. 2010;103:845-51 pubmed publisher
immunohistochemistry; human; 1:100	Won Y, Park Y, Ahn M, Do I, Ko Y, Park K. A phase II study of combination chemotherapy with capecitabine and cisplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck. Ann Oncol. 2011;22:417-23 pubmed publisher
immunohistochemistry; human; 1:300	Chen C, Chen L, Liang Y, Tsang N, Chang Y. Epstein-Barr virus latent membrane protein 1 induces the chemotherapeutic target, thymidine phosphorylase, via NF-kappaB and p38 MAPK pathways. Cell Signal. 2010;22:1132-42 pubmed publisher
immunohistochemistry; human; 1:4000	Brockenbrough J, Morihara J, Hawes S, Stern J, Rasey J, Wiens L, et al. Thymidine kinase 1 and thymidine phosphorylase expression in non-small-cell lung carcinoma in relation to angiogenesis and proliferation. J Histochem Cytochem. 2009;57:1087-97 pubmed publisher
immunohistochemistry - paraffin section; rat; loading ...; fig 2B (c) immunohistochemistry - paraffin section; mouse; loading ...; fig 2A (c)	Chihara Y, Fujimoto K, Miyake M, Hiasa Y, Hirao Y. Anti-tumor effect of cimetidine via inhibiting angiogenesis factors in N-butyl-N-(4-hydroxybutyl) nitrosamine-induced mouse and rat bladder carcinogenesis. Oncol Rep. 2009;22:23-8 pubmed
immunohistochemistry; human; 1:5000	Koopman M, Venderbosch S, Van Tinteren H, Ligtenberg M, Nagtegaal I, van Krieken J, et al. Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study. Eur J Cancer. 2009;45:1999-2006 pubmed publisher
immunohistochemistry; human; 1:500 western blot; human; 1:500	Chi L, Lee C, Chang K, Hao S, Lee H, Liang Y, et al. Enhanced interferon signaling pathway in oral cancer revealed by quantitative proteome analysis of microdissected specimens using 16O/18O labeling and integrated two-dimensional LC-ESI-MALDI tandem MS. Mol Cell Proteomics. 2009;8:1453-74 pubmed publisher
immunohistochemistry; human; 1:40	Han S, Oh D, Im S, Park S, Lee K, Song H, et al. Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer. Br J Cancer. 2009;100:298-304 pubmed publisher
ELISA; human; 0.5 ug/ml	Brostjan C, Gebhardt K, Gruenberger B, Steinrueck V, Zommer H, Freudenthaler H, et al. Neoadjuvant treatment of colorectal cancer with bevacizumab: the perioperative angiogenic balance is sensitive to systemic thrombospondin-1 levels. Clin Cancer Res. 2008;14:2065-74 pubmed publisher
immunohistochemistry; human; 1:200	Friedman J, Dunn R, Wood D, Vaishampayan U, Wu A, Bradley D, et al. Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer. J Urol. 2008;179:911-5; discussion 915-6 pubmed publisher
immunohistochemistry; human; 1:100	Lee J, Im Y, Cho E, Hong Y, Lee H, Kim H, et al. A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma. Cancer Chemother Pharmacol. 2008;62:77-84 pubmed
immunohistochemistry; human; 1:100	Ranieri G, Grammatica L, Patruno R, Zito A, Valerio P, Iacobellis S, et al. A possible role of thymidine phosphorylase expression and 5-fluorouracil increased sensitivity in oropharyngeal cancer patients. J Cell Mol Med. 2007;11:362-8 pubmed
immunohistochemistry; human; 1:100	Mangia A, Chiriatti A, Ranieri G, Abbate I, Coviello M, Simone G, et al. H pylori status and angiogenesis factors in human gastric carcinoma. World J Gastroenterol. 2006;12:5465-72 pubmed
immunohistochemistry; human; 10 ug/ml	Wang E, Goh Y, Moon I, Park C, Lee K, Kang S, et al. Upregulation of thymidine phosphorylase in chronic glomerulonephritis and its role in tubulointerstitial injury. Nephron Clin Pract. 2006;102:c133-42 pubmed
immunohistochemistry; human; 1:400	Stavropoulos N, Bouropoulos C, Ioachim E, Michael M, Hastazeris K, Tsimaris I, et al. Prognostic significance of thymidine phosphorylase in superficial bladder carcinoma. Int Urol Nephrol. 2005;37:55-60 pubmed
	Brostjan C, Bayer A, Zommer A, Gornikiewicz A, Roka S, Benkö T, et al. Monitoring of circulating angiogenic factors in dendritic cell-based cancer immunotherapy. Cancer. 2003;98:2291-301 pubmed
	Heffelfinger S, Miller M, Yassin R, Gear R. Angiogenic growth factors in preinvasive breast disease. Clin Cancer Res. 1999;5:2867-76 pubmed

product information

Product Type :

Antibody

Product Name :

Thymidine Phosphorylase Monoclonal Antibody (P-GF.44C)

Catalog # :

MA1-46059

Quantity :

100 µg

Price :

US 470

Clonality :

Monoclonal

Purity :

protein A

Host :

Mouse

Reactivity :

Human

Applications :

Immunocytochemistry: 1:10-1:500, Immunohistochemistry (Paraffin): 1:10-1:500, Immunoprecipitation: 1:10-1:500, Western Blot: 1:100-1:2,000

Species :

Human

Clone :

P-GF.44C

Isotype :

IgG1

Storage :

4° C, do not freeze

Description :

A platelet-derived endothelial growth factor (PD-ECGF), same as thymidine phosphorylase (TP) or gliostatin. In the presence of inorganic orthophosphate, it catalyses the reversible phospholytic cleavage of thymidine and deoxyuridine to their corresponding bases and 2-deoxyribose-1-phosphate. It is both chemotactic and mitogenic for endothelial cells and a non-heparin binding angiogenic factor present in platelets. It is also involved in transformation of fluoropyrimidines, cytotoxic agents used in the treatment of a variety of malignancies, into active cytotoxic metabolites.

Immunogen :

Full length human protein in E. coli

Format :

Liquid

Applications w/Dilutions :

Immunocytochemistry: 1:10-1:500, Immunohistochemistry (Paraffin): 1:10-1:500, Immunoprecipitation: 1:10-1:500, Western Blot: 1:100-1:2,000

Aliases :

2900072D10Rik; ECGF; Ecgf1; endothelial cell growth factor 1 (platelet-derived); gliostatin; hPD-ECGF; MEDPS1; MNGIE; MTDPS1; OTTHUMP00000196767; OTTHUMP00000196770; PD TP; PDECGF; PD-ECGF; Pdgfec; platelet derived growth factor, endothelial cell; Platelet-derived endothelial cell growth factor; TdRPase; thymidine phosphorylase; TP; TYMP

more info or order :

Invitrogen product webpage